FIELD: medicine.
SUBSTANCE: invention refers to medicine and concerns a method of treating insulin resistance. A peripherally effective amount of melanocortin receptor-4 agonist is introduced in a patient. The melanocortin receptor-4 agonist represents cyclic peptides containing the core sequence His-D-Phe-Arg-Trp-Cys.
EFFECT: invention provides effective treatment of insulin resistance by the peptide melanocortin receptor-4 agonist in the peripheral introduction.
34 cl, 11 dwg, 13 tbl
Title | Year | Author | Number |
---|---|---|---|
LIGANDS OF MELANOCORTIN RECEPTORS | 2006 |
|
RU2401841C2 |
METHOD FOR TREATMENT OF DISORDERS ASSOCIATED WITH MELANOCORTIN 4 RECEPTOR PATH | 2016 |
|
RU2785889C1 |
MELANOCORTIN RECEPTOR LIGANDS | 2006 |
|
RU2439079C2 |
MELANOCORTIN RECEPTOR LIGANDS | 2006 |
|
RU2380372C2 |
GLP-1 ANALOGUES | 1999 |
|
RU2208015C2 |
ALPHA- AND GAMMA-MSH ANALOGUES | 2013 |
|
RU2668791C2 |
HYDANTOIN MODIFIED MELANOCORTIN RECEPTOR LIGANDS | 2008 |
|
RU2450017C2 |
PEPTIDIC INTERLEUKIN-23 RECEPTOR INHIBITORS FOR ORAL ADMINISTRATION AND USE THEREOF FOR TREATING INFLAMMATORY INTESTINAL DISEASES | 2015 |
|
RU2736637C2 |
KV1_3 BLOCKERS | 2020 |
|
RU2825633C1 |
DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
Authors
Dates
2012-06-20—Published
2008-11-05—Filed